Ultimovacs ASA
🇳🇴Norway
- Country
- 🇳🇴Norway
- Ownership
- Public
- Established
- 2011-01-01
- Employees
- 25
- Market Cap
- -
- Website
- http://www.ultimovacs.com
TENDU Vaccine in Patients With Relapse After Primary Radical Prostatectomy
- First Posted Date
- 2021-01-08
- Last Posted Date
- 2024-07-08
- Lead Sponsor
- Ultimovacs ASA
- Target Recruit Count
- 12
- Registration Number
- NCT04701021
- Locations
- 🇳🇴
Oslo University Hospital, The Norwegian Radium Hospital, Oslo, Norway
UV1 Vaccination Plus Nivolumab and Ipilimumab in Treatment of Melanoma
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2020-05-11
- Last Posted Date
- 2024-04-18
- Lead Sponsor
- Ultimovacs ASA
- Target Recruit Count
- 156
- Registration Number
- NCT04382664
- Locations
- 🇺🇸
Highlands Oncology Group, Fayetteville, Arkansas, United States
🇺🇸California Cancer Associates for Research & Excellence (CCARE, San Marcos, California, United States
🇺🇸University of California Irvine Health, Orange, California, United States
UV1 Vaccine With Pembrolizumab for Patients With Unresectable or Metastatic Melanoma
- First Posted Date
- 2018-05-29
- Last Posted Date
- 2024-08-22
- Lead Sponsor
- Ultimovacs ASA
- Target Recruit Count
- 30
- Registration Number
- NCT03538314
- Locations
- 🇺🇸
John Wayne Cancer Center, Santa Monica, California, United States
🇺🇸St. Luke's University Health Network, Easton, Pennsylvania, United States
🇺🇸University of Iowa Carver College of Medicine, Iowa City, Iowa, United States
Safety of UV1 Vaccination in Combination With Ipilimumab in Patients With Unresectable or Metastatic Malignant Melanoma
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2014-10-27
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Ultimovacs ASA
- Target Recruit Count
- 12
- Registration Number
- NCT02275416
- Locations
- 🇳🇴
Oslo University Hospital, Radiumhospitalet, Oslo, Norway
A Phase I/IIa Study of UV1 Vaccination in Patients With Non Small Cell Lung Cancer.
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2013-02-11
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Ultimovacs ASA
- Target Recruit Count
- 18
- Registration Number
- NCT01789099
- Locations
- 🇳🇴
Oslo University Hospital, Oslo, Norway
A Phase I/IIa Study of UV1 Vaccine in Patients With Prostate Cancer
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2013-02-06
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Ultimovacs ASA
- Target Recruit Count
- 22
- Registration Number
- NCT01784913
- Locations
- 🇳🇴
Oslo University Hospital, Oslo, Norway
© Copyright 2024. All Rights Reserved by MedPath